# A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)

Study · id `cardio:ct-nct06269107` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06269107](<https://clinicaltrials.gov/study/NCT06269107>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06269107

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 485 participants.

## Technical summary

Registry record NCT06269107. Randomized; no masking; primary purpose treatment. Start 2024-02-15 (actual); primary completion 2025-05-27 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 485 participants (enrolled count; ClinicalTrials.gov record NCT06269107, source copy `cardio:ctgov-nct06269107-2026-06-05`, retrieved 2026-10-26)
- Started: 2024-02-15 (actual) (ClinicalTrials.gov record NCT06269107, source copy `cardio:ctgov-nct06269107-2026-06-05`, retrieved 2026-10-26)
- Primary completion: 2025-05-27 (actual) (ClinicalTrials.gov record NCT06269107, source copy `cardio:ctgov-nct06269107-2026-06-05`, retrieved 2026-10-26)
- Completion: 2025-07-08 (actual) (ClinicalTrials.gov record NCT06269107, source copy `cardio:ctgov-nct06269107-2026-06-05`, retrieved 2026-10-26)
- Countries: United States; China; Greece; India; Italy; Japan; Poland; Puerto Rico; South Africa; Türkiye (ClinicalTrials.gov record NCT06269107, source copy `cardio:ctgov-nct06269107-2026-06-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06269107-2026-06-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
- Acronym: COMBINE 4
- Condition: Type 2 Diabetes
- Intervention (Drug): IcoSema
- Intervention (Drug): Insulin glargine
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial (`cardio:pubmed-42594928`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 81790d02273d5ef84920c17486c98c12da99b9024e4d7a6e3012e01d33cb574c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
